<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835742</url>
  </required_header>
  <id_info>
    <org_study_id>PAGE</org_study_id>
    <nct_id>NCT02835742</nct_id>
  </id_info>
  <brief_title>Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan</brief_title>
  <official_title>Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niigata University Medical &amp; Dental Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Niigata University Medical &amp; Dental Hospital</source>
  <brief_summary>
    <textblock>
      Objective: Determine the safety and efficacy of GM-CSF inhalation in patients with aPAP.&#xD;
&#xD;
      Study Design: multi-center, randomized, double-blind, placebo- controlled, safety/efficacy&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change value of AaDO2 between baseline and 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Pulmonary Alveolar Proteinosis, Autoimmune</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatments for Group 1 include GM-CSF inhalation with 250 mcg/day/body of sargramostim (125 mcg BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatments for Group 2 include placebo inhalation (Placebo BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <arm_group_label>Group1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age over 16 years and below 80 years (as of the date of registration).&#xD;
&#xD;
          2. Can provide signed informed consent.&#xD;
&#xD;
          3. Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study procedures specified in the protocol (including short-term hospital&#xD;
             admission).&#xD;
&#xD;
          4. Autoimmune pulmonary alveolar proteinosis diagnosed by both HR-CT and biopsy and/or&#xD;
             BAL as well as GM-CSF antibodies in serum positive.&#xD;
&#xD;
          5. PaO2 &lt; 70 mmHg after 5 minutes spine position at room air, or PaO2 &lt; 75 mmHg after 5&#xD;
             minutes spine position at room air and with symptom(s) including cough, sputum and&#xD;
             exertional dyspnea&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosed as secondary or hereditary pulmonary alveolar proteinosis&#xD;
&#xD;
          2. WBC of 12,000/mm3 or more&#xD;
&#xD;
          3. Fever of 38 degree celsius or more&#xD;
&#xD;
          4. Severe edema&#xD;
&#xD;
          5. History of malignant disease within recent 5 years (not applied to the treated cases&#xD;
             of uterine carcinoma in situ and local basal cell carcinoma)&#xD;
&#xD;
          6. Complication of cardiovascular diseases including congestive heart failure, angina&#xD;
             pectoris, hemorrhagic tendency, etc with severe condition.&#xD;
&#xD;
          7. Complication of respiratory diseases such as pulmonary infectious disease(incl.&#xD;
             pulmonary tuberculosis), bronchial asthma, lung fibrosis ,interstitial pneumonitis, or&#xD;
             bronchiectasis, in which the evaluations of safety and efficacy of GM-CSF therapy are&#xD;
             considered as difficult.&#xD;
&#xD;
          8. History or complication of infectious diseases which require systemic administration&#xD;
             of antibiotics, antifungal or antiviral agents within recent 2 weeks.&#xD;
&#xD;
          9. Treatment with other cytokines&#xD;
&#xD;
         10. Pregnant or possibly pregnant women, lactating women, and women who desire to become&#xD;
             pregnant during the study period&#xD;
&#xD;
         11. Patients who have been treated with whole-lung lavage, repeated segmental-lung lavage,&#xD;
             or rituximab within 6 months before the start of the study (this criterion does not&#xD;
             apply to patients for whom 6 months or more have elapsed after their last lavage or&#xD;
             rituximab)&#xD;
&#xD;
         12. Severe liver dysfunction (AST &gt; 100 IU/L and/or ALT &gt; 100 IU/L and/or T-bil &gt;3.0mg/dL)&#xD;
&#xD;
         13. Severe renal dysfunction (Ccr &lt; 30 mL/min, calculated by Cockcroft-Gault (CG) formula)&#xD;
&#xD;
         14. Previous experience of severe and unexplained side-effects during aerosol delivery of&#xD;
             any kind of medicinal product&#xD;
&#xD;
         15. Treatment with oral or intravenous administration or inhalation of corticosteroids.&#xD;
&#xD;
         16. Treatment with other inhaled drugs.&#xD;
&#xD;
         17. Previously treated with GM-CSF before the start of the study.&#xD;
&#xD;
         18. Demonstrate hypersensitivity to GM-CSF agent.&#xD;
&#xD;
         19. Other patients judged to be inappropriate for the study by the attending physician&#xD;
             (e.g., patients who are unlikely to complete treatment or are uncooperative).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Niigata University Med &amp; Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <last_update_submitted>February 6, 2019</last_update_submitted>
  <last_update_submitted_qc>February 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

